Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They presently have a $11.00 price target on the stock. Needham & Company LLC's price target would suggest a potential upside of 90.97% from the company's previous close.

A number of other equities analysts have also recently commented on RXRX. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $8.20.

Recursion Pharmaceuticals Stock Up 27.7 %

Shares of RXRX stock traded up $1.25 during trading hours on Tuesday, hitting $5.76. 83,130,078 shares of the company's stock traded hands, compared to its average volume of 11,740,171. The stock's fifty day simple moving average is $6.83 and its two-hundred day simple moving average is $6.84. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -3.76 and a beta of 1.00. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter in the prior year, the firm earned ($0.42) EPS. The firm's revenue for the quarter was down 57.8% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $26,000. Private Trust Co. NA purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $27,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.